Isomorphic Labs has raised $5 billion in an oversubscribed Series C financing to expand its artificial intelligence drug-design platform and advance internally developed and partnered therapeutic candidates toward clinical trials.
Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz and several other new investors also participated, while Alphabet made an additional significant investment.
All existing investors joined the financing, including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.
Isomorphic Labs will use the capital to develop additional foundational AI models, expand its drug pipeline, build translational and clinical development capabilities, and establish global infrastructure for AI-led bioengineering.
Scaling The IsoDDE Drug Design Engine
Isomorphic Labs has developed a proprietary drug-design system called IsoDDE.
The platform combines foundational simulation models that work across multiple therapeutic areas and types of medicines. It is intended to help researchers explore large chemical spaces, design molecules, and optimize characteristics relevant to potential drugs.
Developing a medicine requires balancing many properties. A molecule may need to interact with a specific biological target while remaining stable, reaching the intended tissue, avoiding harmful interactions, and possessing characteristics suitable for manufacturing and administration.
IsoDDE is designed to model several of these considerations and help Isomorphic’s scientists refine potential candidates before and during laboratory testing.
The platform also includes proprietary AI agents that reason across complex biological systems. Isomorphic uses these tools to investigate disease mechanisms and identify possible approaches to designing new treatments.
The company says its simulation models are moving predictions closer to experimental accuracy. Those claims have not been independently validated through approved medicines, and the company’s therapeutic programs remain in preclinical development.
Advancing Oncology And Immunology Programs
Isomorphic Labs is building a multi-modality pipeline covering different therapeutic approaches and disease areas.
Its internal programs currently include potential treatments in oncology and immunology. The company is also advancing candidates through collaborations with external partners.
Isomorphic said these programs have produced positive preclinical results and are preparing to move toward clinical development.
Preclinical results involve laboratory and animal studies conducted before testing a candidate in humans. Compounds that perform well at this stage still face substantial scientific, regulatory, manufacturing, and clinical risks.
The new funding will support the infrastructure needed to transition candidates into clinical trials. This includes translational research, manufacturing preparation, regulatory work, and the design and operation of clinical development programs.
Isomorphic has not disclosed which internal candidate will enter the clinic first or provided a specific clinical-trial timeline.
Developing New Foundational Biology Models
Beyond its existing drug-design models, Isomorphic plans to expand into additional areas of biology.
The company is building foundational models intended to represent biological systems at a molecular level. It believes these systems could improve researchers’ understanding of disease mechanisms and make it easier to design therapeutics with targeted properties.
Isomorphic is also developing a partner ecosystem focused on mechanistic disease biology. These collaborations are expected to provide additional biological knowledge, experimental data, and therapeutic-development experience.
The company’s long-term objective is to build a reusable drug-design engine rather than a platform focused on only one disease or type of molecule.
If successful, the approach could allow Isomorphic to apply the same underlying infrastructure to multiple therapeutic areas and drug modalities.
Building AI-Led Bioengineering Infrastructure
A portion of the Series C proceeds will fund global computing, research, and development infrastructure.
AI drug design requires large amounts of computing capacity, specialized scientific data, laboratory validation, and teams spanning machine learning, chemistry, biology, pharmacology, and clinical development.
Isomorphic plans to integrate these functions through an AI-first development model. The company will continue hiring researchers and drug-development professionals while expanding the systems supporting its models and therapeutic programs.
The business is headquartered in London and has offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
Founded in 2021, Isomorphic Labs is led by founder and CEO Sir Demis Hassabis and President Max Jaderberg.
The company operates as an Alphabet-backed business but has also raised capital from external institutional investors.
The $5 billion round gives Isomorphic substantial resources to fund the expensive transition from preclinical research into human trials. However, the company will still need to demonstrate that its AI-designed candidates can meet established standards for safety and effectiveness.
KEY QUOTES:
“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI. Our drug design engine is generating molecules with unprecedented precision and speed. This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
Sir Demis Hassabis, Founder and Chief Executive Officer of Isomorphic Labs
“Every week we are making repeatable scientific advancements enabled by our models. These translate directly into better molecular profiles with the potential to be new medicines and unlock some of the hardest problems in drug discovery. Our interdisciplinary teams combine world-leading machine learning researchers with top-class drug hunters and together they are routinely solving complex biological problems that have stalled traditional research for decades. We are translating our discoveries directly into potential life-changing medicines, built on the infrastructure we are establishing for the future of bioengineering with this investor backing.”
Max Jaderberg, President of Isomorphic Labs
“Discovering and developing new medicines is an optimization challenge of almost infinite scale. Isomorphic is transforming that journey, building deep learning systems that can predict complex biological behaviors with remarkable accuracy and systematically map the path to new medicines. We believe Demis, Max, and the Isomorphic team are building the future of AI-led drug discovery and we are proud to partner with them on this essential mission.”
Neil Mehta, Founder and Managing Partner of Greenoaks
“Isomorphic Labs is building foundational technology for the future of medicine. It’s inspiring to see the Isomorphic team translate advanced AI into a growing portfolio of drug candidates. Using AI to improve human health is one of the most important challenges of our generation. We’re proud to co-lead this round and help further scientific discovery in medicine.”
Konstantine Buhler, Partner at Sequoia Capital

